Skip to content
TrackPodcasts
scienceJul 27, 202436:40pending

TWiV 1134: Clinical update with Dr. Daniel Griffin

About this episode

In his weekly clinical update, Dr. Griffin discusses Merck's RSV preventative monoclonal antibody Clesrovimab before reviewing the recent statistics on SARS-CoV-2 infection, if previous SARS-COV-2 infections predict the outcome of subsequent infections, if using COVID rapid diagnostic tests is cost effective, if the protein based vaccine NVX-CoV2327 elicits a durable immune response, if combination treatment of vaccine and antiviral drugs effectively protect against hospitalization, where to find PEMGARDA, what do when healthcare workers succumb to SARS-CoV-2 infection, and how COVID-19 may alter the cognitive trajectories of older patients.

Subscribe (free): Apple PodcastsGoogle PodcastsRSSemail

Become a patron of TWiV!

Intro music is by Ronald Jenkees

Send your questions for Dr. Griffin to [email protected]

Get every episode summarized

Each time This Week in Virology publishes, we email you a written briefing from the transcript — the topics, who appeared, and any specific claims, with the ad reads skipped.

Email me new episodes

Free for 3 shows. No card needed.

Hosts & guests

No transcript yet

This episode has not been transcribed. Request it and it moves to the front of the queue.

TWiV 1134: Clinical update with Dr. Daniel Griffin

This Week in Virology

0:00
36:40

More episodes

More from This Week in Virology

View all episodes →